Incline therapeutics acquires Ionsys assets to tempt Cadence into minority shareholding and option deal worth up to $290m.
Nasdaq-listed Cadence Pharmaceuticals has taken a minority stake in pain relief research company Incline Therapeutics as part of an option deal to acquire the company for up to $290m.
Cadence is primarily interested in Incline’s Ionsys, needle-free pain treatment. Incline acquired the rights to Ionsys from Alza, a subsidiary of healthcare company Johnson & Johnson, at the same time as signing the option with Cadence and agreeing $43m in a series A round from venture capital firms led by Frazier…
